Moderna (NASDAQ:MRNA) Stock Price Down 5% – Should You Sell?

Shares of Moderna, Inc. (NASDAQ:MRNA) dropped 5% on Tuesday . The stock traded as low as $37.43 and last traded at $37.53. Approximately 4,625,405 shares were traded during trading, a decline of 3% from the average daily volume of 4,750,971 shares. The stock had previously closed at $39.51.

Analysts Set New Price Targets

MRNA has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and dropped their target price for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. JPMorgan Chase & Co. decreased their price objective on Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a report on Monday, November 4th. Wolfe Research initiated coverage on shares of Moderna in a report on Friday. They set an “underperform” rating and a $40.00 target price for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 target price on shares of Moderna in a research report on Thursday, September 19th. Finally, TD Cowen lowered their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Moderna has an average rating of “Hold” and a consensus price target of $84.00.

Moderna Trading Down 5.6 %

The business has a fifty day moving average price of $57.82 and a two-hundred day moving average price of $96.07. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $14.35 billion, a PE ratio of -6.59 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.39) EPS. Analysts expect that Moderna, Inc. will post -9.43 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This represents a 13.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 2,930 shares of company stock worth $217,170. Company insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Moderna

A number of large investors have recently modified their holdings of the company. State Street Corp increased its holdings in shares of Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Wellington Management Group LLP increased its stake in Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Moderna by 0.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after purchasing an additional 19,819 shares in the last quarter. Finally, Capital World Investors lifted its position in shares of Moderna by 0.5% during the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after buying an additional 18,728 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.